Black Diamond Therapeutics (NASDAQ:BDTX) used a presentation at the 46th annual TD Cowen Healthcare Conference to highlight ...

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...

Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...

Oct. 7, 2005 — The U.S. Food and Drug Administration (FDA) has approved an assay for the detection of epidermal growth factor receptor mutations in patients with non-small cell lung cancer; a D-dimer ...

The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.

Retrospective review of 33,850 molecularly profiled ovarian cancer samples from real-world patients who underwent next-generation sequencing (NGS) of DNA between 2016 and 2025. EGFR-mutated cases were ...

Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine. Panelists discuss how understanding EGFR mutations has transformed the ...

Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...

SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform ...

Hematoxylin and eosin staining revealed poorly differentiated carcinoma with round cells and rhabdoid morphology (A, 100×). Positive expression of CK5/6 (B, 100×) and CK7 (C, 100×). Suggestive SMARCA4 ...